STOCK TITAN

Safe Harbor Financial Applauds Historic Federal Cannabis Rescheduling Action, Citing Potential Benefits to Operator Economics, Deposit Quality, and Total Addressable Market

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Positive)
Tags

Safe Harbor Financial (NASDAQ: SHFS) responded to the DOJ order that moved FDA-approved cannabis products and qualifying state-licensed medical marijuana into Schedule III, effective April 22, 2026. The order removes Section 280E’s deduction disallowance for qualifying medical operators, establishes a 60-day expedited DEA registration pathway for early applicants, and preserves existing Bank Secrecy Act obligations.

Safe Harbor expects the change to potentially improve operator cash flow, deposit stability, credit profiles, and demand for its managed compliance and banking services.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • 280E relief for qualifying medical operators (improves cash flow)
  • DEA to process qualifying DEA registration applications within 60 days
  • Expanded TAM as more banks may enter cannabis banking
  • Platform supported >$29 billion in cannabis deposits over the past decade

Negative

  • Order excludes adult-use cannabis from Schedule III relief
  • Bank Secrecy Act, SAR/CTR reporting, and enhanced due diligence remain unchanged
  • Operators with both medical and adult-use licenses must segregate books, adding compliance complexity

News Market Reaction – SHFS

+9.56%
9 alerts
+9.56% News Effect
+16.7% Peak in 8 hr 28 min
+$381K Valuation Impact
$4.37M Market Cap
0.9x Rel. Volume

On the day this news was published, SHFS gained 9.56%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.7% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $381K to the company's valuation, bringing the market cap to $4.37M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Historical tax rate: 70% or higher Effective rescheduling date: April 22, 2026 DEA processing timeline: 60 days +3 more
6 metrics
Historical tax rate 70% or higher Effective federal tax rates on qualifying medical cannabis operators under 280E
Effective rescheduling date April 22, 2026 Date medical marijuana and certain cannabis products moved to Schedule III
DEA processing timeline 60 days Target for DEA to process certain medical operator registrations submitted early
Cannabis deposits handled More than $29 billion Cannabis-related deposits facilitated by Safe Harbor over the past decade
Administrative hearing start June 29, 2026 Start of expedited DOJ hearing on broader marijuana rescheduling
Hearing deadline July 15 Date by which the expedited rescheduling hearing must conclude

Market Reality Check

Price: $0.4099 Vol: Volume 826,750 is 2.19x t...
high vol
$0.4099 Last Close
Volume Volume 826,750 is 2.19x the 20-day average of 377,886, signaling elevated trading interest ahead of this policy update. high
Technical Shares at 0.8701 are trading below the 200-day MA of 2.2 and remain deep under the 9.19 52-week high.

Peers on Argus

SHFS fell 10.81% while regional bank peers showed mixed, generally modest moves ...

SHFS fell 10.81% while regional bank peers showed mixed, generally modest moves (e.g., CARV up 15.69%, GLBZ up 0.2%, KFFB down 0.68%). With no peers in the momentum scanner and no same-day peer headlines, today’s reaction appears stock-specific rather than a broad sector rotation.

Historical Context

5 past events · Latest: Apr 21 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Apr 21 New product launch Positive +5.7% Launch of pooled 401(k) plan tailored to state-legal cannabis employers.
Apr 16 Earnings report Negative -4.1% Q4 and 2025 results with full-year revenue decline versus 2024 despite balance sheet gains.
Apr 01 Preliminary earnings Negative -3.7% Preliminary Q4 and 2025 showing revenue halving to $7.7M from $15.2M.
Mar 09 Strategic update Positive +16.6% CEO letter highlighting debt elimination, > $6M cash and enhanced PCCU economics.
Mar 03 Deposit growth update Positive +4.9% Report of 29% YoY emerging-market deposit growth and 100+ new accounts.
Pattern Detected

Across recent news and earnings, SHFS shares have generally moved in the same direction as the tone of the announcements, with positive strategic updates drawing gains and mixed/weak fundamentals seeing declines.

Recent Company History

Over the past two months, SHFS has focused on balance sheet repair and growth in cannabis banking. On Mar 3, 2026, it highlighted 29% emerging-market deposit growth and 100+ new depository accounts, followed by a 16.58% jump after a Mar 9 CEO letter emphasizing debt elimination and > $6 million cash. Preliminary and final Q4 2025 results on Apr 1 and Apr 16 showed revenue contraction versus 2024 but improving loan economics, which drew modest declines. A new cannabis-focused 401(k) product on Apr 21 coincided with a 5.65% rise, underscoring sensitivity to growth-oriented news.

Market Pulse Summary

The stock moved +9.6% in the session following this news. A strong positive reaction aligns with SHF...
Analysis

The stock moved +9.6% in the session following this news. A strong positive reaction aligns with SHFS’s history of outsized moves on favorable cannabis and strategic updates, such as the 16.58% rise after the Mar 9, 2026 CEO letter. The removal of 280E for qualifying medical operators and a pathway to broader rescheduling directly support the company’s banking and managed-services thesis. Investors have previously rewarded balance sheet repair and deposit growth; sustained gains would depend on operators’ execution and policy follow-through.

Key Terms

280E, schedule iii, controlled substances act, dea, +4 more
8 terms
280E regulatory
"This order removes the 280E tax burden from qualifying state-licensed medical cannabis operators"
Section 280E is a U.S. tax rule that forbids businesses from claiming ordinary business expense deductions if they are treated as trafficking in federally controlled substances. For investors, that means companies in affected industries can report strong sales but still face much higher effective tax rates and lower cash profits—like running a shop that must pay full sales taxes on gross receipts without subtracting rent or payroll—making earnings and valuation comparisons harder.
schedule iii regulatory
"order moving state-licensed medical marijuana and FDA-approved cannabis products from Schedule I to Schedule III"
A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.
controlled substances act regulatory
"from Schedule I to Schedule III of the Controlled Substances Act, effective April 22, 2026"
A federal law that creates the rules for which drugs and chemicals are legal, how they are classified by risk, and what licenses and controls are required for manufacture, distribution, research, and medical use. For investors, these classifications act like traffic signals — they determine how easy or hard it is for companies to develop, sell, or research certain medications and can sharply affect a company’s regulatory cost, market access, and legal risk.
dea regulatory
"registration structure. The most commercially significant element of the order is the removal ... within the DEA registration structure"
The DEA is the U.S. Drug Enforcement Administration, the federal agency that enforces laws on controlled substances and issues licenses for handling regulated drugs. It matters to investors because DEA actions—such as granting or revoking registrations, issuing enforcement actions, or scheduling substances—can directly affect a company’s ability to manufacture, distribute, research, or sell certain pharmaceuticals, similar to how a traffic controller can speed up or stop movement on a busy road.
bank secrecy act regulatory
"it does not alter Bank Secrecy Act obligations, FinCEN guidance, SAR/CTR reporting requirements"
A federal law that requires banks and other financial firms to keep detailed records of large cash transactions and report suspicious activity to government authorities. Think of it as rules that force banks to keep clear ledgers and alert regulators when money moves look unusual. For investors, compliance affects a bank’s costs, legal and reputational risk, and the transparency used to judge the safety and conduct of financial institutions.
fincen regulatory
"does not alter Bank Secrecy Act obligations, FinCEN guidance, SAR/CTR reporting requirements"
A bureau of the U.S. Treasury that monitors and shares information about suspicious financial activity to prevent money laundering, fraud, and financing of crime. Think of it as a financial ‘watchdog’ that requires banks and some businesses to report unusual transactions and issues guidance for tracking cash flows; its actions matter to investors because its rules and investigations can lead to fines, operational changes, or tighter controls that affect a company’s costs, reputation, and regulatory risk.
sar/ctr reporting regulatory
"does not alter Bank Secrecy Act obligations, FinCEN guidance, SAR/CTR reporting requirements"
SAR/CTR reporting are mandatory filings financial firms send to regulators when they detect suspicious behavior or large cash movements: a Suspicious Activity Report (SAR) flags transactions that look unusual or possibly illegal, while a Currency Transaction Report (CTR) records cash transactions above a set threshold. Think of it as a neighborhood watch notifying authorities when activity looks out of place; for investors, these filings matter because they reveal regulatory oversight, potential fraud or money‑laundering risks, and can lead to investigations, fines, or restrictions that affect a company’s reputation and stock value.
safer banking act regulatory
"A durable, comprehensive solution for cannabis banking will ultimately require passage of the SAFER Banking Act"
A Safer Banking Act is legislation designed to reduce the risk of bank failures and protect customers by tightening rules on capital, liquidity, oversight and resolution planning—think of it as adding stronger seatbelts and routine inspections to the financial system. It matters to investors because such laws change how banks lend, manage risk and absorb losses, which can alter profitability, credit availability and the perceived safety of bank stocks and bond holdings.

AI-generated analysis. Not financial advice.

New DOJ Order Removes 280E Tax Burden for State-Licensed Medical Cannabis Operators, Potentially Expanding Safe Harbor's Client Base and Managed Services Opportunity

DENVER, April 24, 2026 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, today issued the following statement in response to the Acting Attorney General’s order moving state-licensed medical marijuana and FDA-approved cannabis products from Schedule I to Schedule III of the Controlled Substances Act, effective April 22, 2026. The order applies narrowly to FDA-approved cannabis products and qualifying state-licensed medical marijuana operators and does not extend to adult-use cannabis.

“The final order from Acting Attorney General Todd Blanche is the most significant federal action on cannabis policy in more than fifty years, and positions Safe Harbor to potentially benefit from resulting improvements across operator financial health and banking activity,” said Terry Mendez, CEO of Safe Harbor Financial. “This order removes the 280E tax burden from qualifying state-licensed medical cannabis operators, which have historically faced effective federal tax rates of 70% or higher on gross profit rather than net income. Stronger operators typically translate into more stable deposits, improved credit profiles, and more durable banking relationships. These are core drivers of our business.”

Understanding the Order and Its Potential Impact on Safe Harbor

The DOJ action moves two specific categories of marijuana into Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a qualifying state medical marijuana license. The effective date is April 22, 2026. The order relies heavily on existing state regulatory frameworks, allowing qualifying operators to continue using state-level systems for recordkeeping, security, and operations within the DEA registration structure.

The most commercially significant element of the order is the removal of Section 280E’s deduction disallowance for qualifying state-licensed medical operators. For years, 280E imposed effective federal tax rates of 70% or higher on cannabis businesses, taxing gross profit rather than net income. That burden being lifted is expected to materially improve operator cash flow, financial transparency, and credit quality factors that are foundational to the banking relationships Safe Harbor supports.

The order also establishes an expedited DEA registration pathway for state-licensed medical manufacturers, distributors, and dispensers, directing the DEA to process applications within 60 days for those submitted within the first six months after publication. State-licensed medical operators may lawfully continue to operate during the pendency of their applications.

Potential Opportunities for Safe Harbor’s Business as a Result of Rescheduling Action

The Company believes stronger operator economics could support Safe Harbor’s core banking business. Improved cash flow and credit quality across the medical cannabis operator base is expected to increase deposit predictability, reduce account churn driven by business failures, and improve loan performance across Safe Harbor’s lending portfolio.

In addition, the Company believes this action has the potential to expand Safe Harbor’s total addressable market. As the federal risk profile of cannabis banking shifts, financial institutions that previously viewed the sector as too uncertain will begin exploring participation. Every new bank or credit union entering the cannabis banking space is a potential customer for Safe Harbor’s fully managed compliance, monitoring, and reporting platform; the same infrastructure that has facilitated more than $29 billion in cannabis-related deposits over the past decade.

Finally, the compliance complexity created by this order could increase demand for Safe Harbor’s managed services. Operators holding both medical and adult-use licenses must now segregate books, cost centers, and intercompany arrangements to determine which portions of their operations qualify for Schedule III treatment and 280E relief. Financial institutions serving these operators face the same granular oversight challenge. This is precisely the kind of regulatory complexity that Safe Harbor’s managed services platform is built to address.

What the Order Does Not Change — and Why Safe Harbor’s Core Value Remains Essential

The order does not extend to adult-use or recreational cannabis. It does not federally legalize marijuana. Critically for financial institutions, it does not alter Bank Secrecy Act obligations, FinCEN guidance, SAR/CTR reporting requirements, or enhanced due diligence expectations. Financial institutions serving cannabis-related businesses must continue to operate within the existing federal compliance framework.

This means the compliance infrastructure Safe Harbor has built and operated for nearly a decade remains essential regardless of Schedule III status. Safe Harbor’s model allows banks and credit unions to profitably scale their cannabis banking programs without building costly internal infrastructure — and in an environment where medical and adult-use activities must now be clearly segregated for federal purposes, that value proposition is stronger than ever.

Looking Ahead: Next Steps

The DOJ has announced a new expedited administrative hearing beginning June 29, 2026, to consider the broader proposed rescheduling of all marijuana from Schedule I to Schedule III. That hearing must conclude by July 15, a compressed timeline that signals the administration’s intent to move aggressively. The outcome of that proceeding will determine whether adult-use operators receive comparable federal treatment.

“Any step that strengthens cannabis operators or expands financial institution participation has the potential to grow the long-term opportunity for Safe Harbor’s fully managed banking platform,” added Mr. Mendez. “We have spent a decade building the infrastructure this industry needs to operate compliantly and confidently. Today’s action validates that investment and expands the market we serve. A durable, comprehensive solution for cannabis banking will ultimately require passage of the SAFER Banking Act but today is meaningful progress, and we believe Safe Harbor is positioned to benefit from every step forward.”

About Safe Harbor
Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has facilitated more than $35.4 billion in cannabis-related transactions across 41 states and territories. Through its proprietary Cannabis Banking Solutions™ Platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking to long-term growth, Safe Harbor provides real solutions and personal support — built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Cautionary Statement Regarding Forward-Looking Statements
Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to the rescheduling of cannabis, the passing of the SAFER Banking Act and any other proposed regulations, the potential positive effects of any rescheduling or legislation, trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations and guidance relating to Safe Harbor’s services; Safe Harbor’s growth prospects and Safe Harbor’s market size; Safe Harbor’s projected financial and operational performance, including relative to its competitors and historical performance; success or viability of new product and service offerings Safe Harbor may introduce in the future; the impact volatility in the capital markets, which may adversely affect the price of Safe Harbor’s securities; the outcome of any legal proceedings that have been or may be brought by or against Safe Harbor; and other statements regarding Safe Harbor’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:
ir@SHFinancial.org

Safe Harbor Media Relations Contact:
safeharbor@kcsa.com


FAQ

What did the April 22, 2026 DOJ order change for medical cannabis operators and SHFS?

It moved qualifying state-licensed medical marijuana and FDA-approved cannabis products to Schedule III, removing Section 280E for qualifying operators. According to the company, that relief could improve operator cash flow, credit profiles, and demand for Safe Harbor’s banking and managed compliance services.

How does the 280E change affect Safe Harbor Financial (SHFS) banking services?

The removal of 280E for qualifying operators may improve deposit predictability and loan performance. According to the company, stronger operator finances could reduce account churn and increase demand for its managed compliance and monitoring platform.

What timelines did the DOJ order set for DEA registration for medical cannabis businesses?

The order directs the DEA to process qualifying registration applications within 60 days for those filed in the first six months. According to the company, applicants may lawfully operate while their DEA applications are pending.

Does the DOJ order legalize adult-use cannabis or change bank reporting obligations for SHFS clients?

No; the order does not legalize adult-use cannabis and does not alter BSA, SAR/CTR reporting, or enhanced due diligence requirements. According to the company, financial institutions must continue existing federal compliance practices.

What operational challenges could Safe Harbor clients face after rescheduling on April 22, 2026?

Operators holding both medical and adult-use licenses must segregate books, costs, and intercompany activity to determine 280E eligibility. According to the company, this segregation increases financial and compliance complexity, raising demand for managed services.